Novel antimicrobial spray outperforms silver sulfadiazine in trial

Peceleganan spray was safe and effective at improving the clinical signs and symptoms of skin wound infections, although the effectiveness of bacterial clearance remains uncertain. Authors call for future studies to further verify these findings and investigate mechanism of action.

• This multicenter, open-label, phase 3 trial recruited and followed up 570 adult patients diagnosed with secondary open wound infections from 37 hospitals in China. Patients were randomized in a 2:1 ratio to receive treatment with 2‰ peceleganan spray or 1% silver sulfadiazine (SSD) cream. Of the 558 patients who completed the trial, 361 (64.7%) were men, and the mean age was 48.6 years. Demographic characteristics were similar between groups.
• On day 8, clinical efficacy was achieved by 339 patients (90.4%) in the peceleganan group and 144 (78.7%) in the SSD group (P < .001).
• The rate of adverse events was similar between groups.

Source:

Wei Y, et al. (2024, June 3). JAMA Netw Open. Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38861260/